Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2025 Earnings Call Transcript March 12, 2026 Operator: Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics, Inc. fourth quarter ...

52-week follow-up data from type 1 diabetes (“T1D”) patients in COVALENT-112 who completed ≥80% of protocol-specified dosing with the read-out expected in the second quarter of 2026. 26-week primary ...

Mark Guerin, CPA, CMA, CFM, Annovis' CFO, has an extensive background in biopharma financial operations, including financial reporting, forecasting, internal controls, IPOs, follow-on offerings, and ...

Good morning, everyone. My name is Etzer Darout, Senior Biotech Analyst at Barclays. My pleasure to have Incyte joining us today, day 2 of our conference. With me, I have Bill Meury, President and ...

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy ...

Sjögren-Larsson syndrome (SLS) constitutes a rare genetic disorder manifesting as a complex neurocutaneous condition ...

Welcome to the UBS Global Consumer and Retail Conference here in New York City. My name is Peter Grom. I am the U.S. consumer staples analyst here at UBS. And we are very excited to have joining us ...

Celebrate the impact of women in Port Harcourt with the Top 50 Excellent Entrepreneurs list showcasing remarkable leaders.

Have you ever wondered about the sheer joy of learning something completely unnecessary? There's something magical about ...

Azafaros will host a satellite symposium entitled “The value of conducting an 18-month placebo-controlled study in Rare Diseases: GM1, GM2 and NPC; the NAVIGATE experience” on February 3 at 17:45 PT, ...

Thank you, operator, and thank you all for joining our quarter 4 and fiscal year 2025 earnings call. During the fourth ...

The AngelList co-founder's post inverting Marc Andreessen's fifteen-year-old thesis arrived just weeks before Wall Street ...